Published in Medical Letter on the CDC and FDA, October 13th, 2002
This work is currently performed in part by FDA's Center for Biologics Evaluation and Research (CBER) and in part by CDER.
"FDA's drug and biological product reviews have long been the gold standard for the world," said Crawford. "By carefully combining part of our present biologics review operation responsibilities with our drug review operation, FDA will be optimally positioned to uphold that gold...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA